Amgen Moves To Dismiss And To Stay Regeneron’s Antitrust Case

We previously reported on Regeneron’s antitrust suit against Amgen in the U.S. District Court for the District of Delaware. Amgen recently filed a motion to dismiss Regeneron’s Complaint and a motion to stay the case.

The case concerns Regeneron’s allegation that Amgen has violated antitrust law by engaging “in a persistent exclusionary campaign to deny patients the life-saving benefits of [] Regeneron’s cholesterol-reducing medication, Praluent® (alirocumab).” In its motion to dismiss under Fed. R. Civ. 12(b)(6), Amgen argues that “antitrust law […]

By | August 21st, 2022 ||

Threats Of Antitrust Enforcement In The Supply Chain

With steep inflation and seemingly constant disruptions in supply chains for all manner of goods, the Biden Administration has turned increasingly to antitrust authorities to tame price increases and stem future bottlenecks. These agencies have used the myriad tools at their disposal to carry out their mandate, from targeting companies that use supply disruptions as cover for anti-competitive conduct, to investigating industries with key roles in the supply chain, to challenging vertical mergers that […]

By | August 11th, 2022 ||

Another Step Towards Increased Antitrust Enforcement In Labor Markets

Since the Department of Justice (DOJ) and Federal Trade Commission (FTC) issued the 2016 Antitrust Guidance for Human Resource Professionals indicating that the agencies would criminally prosecute companies for illegal no-poach or wage-fixing agreements, the agencies have not been shy about their increased focus on labor market issues and greater scrutiny of wage-fixing and no-poach agreements. President Biden’s Executive Order on Promoting Competition in the American Economy included initiatives aimed at promoting worker mobility, […]

By | August 1st, 2022 ||